Clinical Trials

For additional information on Cancer Clinical trials at Cedars-Sinai, click here.

 

 

Prostate Cancer

A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY

Principal investigator: Howard Sandler, M.D.
Research coordinator: Heather Chen
Contact: (310) 248-6773

Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen-deprivation therapy is more effective for prostate cancer. This trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.

A RANDOMIZED PHASE II STUDY OF COMBINED ANDROGEN DEPRIVATION VERSUS COMBINED ANDROGEN DEPRIVATION WITH IMC-A12 FOR PATIENTS WITH NEW HORMONE-SENSITIVE METASTATIC PROSTATE CANCER

Principal investigator: Edwin M. Posadas, M.D.
Research coordinator: Amy Oppenheim
Contact: (310) 423-3713

Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, goserelin, or leuprolide acetate, may lessen the amount of androgens made by the body. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether bicalutamide, goserelin, or leuprolide acetate are more effective when given with or without cixutumumab in treating prostate cancer. This randomized phase II trial is studying bicalutamide, goserelin, or leuprolide acetate to see how well they work when given with or without cixutumumab in treating patients with newly diagnosed metastatic prostate cancer.

A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL COMPARING IPILIMUMAB VS. PLACEBO FOLLOWING RADIOTHERAPY IN SUBJECTS WITH CASTRATION RESISTANT PROSTATE CANCER THAT HAVE RECEIVED PRIOR TREATMENT WITH DOCETAXEL

Principal investigator: Edwin M. Posadas, M.D.
Research coordinator: Amy Oppenheim/ Jessica Hamann
Contact: (310) 423-3713 / (310) 248-6737

The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone. Patients must have had previous docetaxel-based chemotherapy. Ipilimumab is a new drug approved by the FDA for use in melanoma that blocks an inhibitor of the immune system.


Kidney Cancer

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PAZOPANIB AS ADJUVANT THERAPY FOR SUBJECTS WITH LOCALIZED OR LOCALLY ADVANCED RENAL CELL CARCINOMA FOLLOWING NEPHRECTOMY

Principal investigator: Hyung L. Kim, M.D.
Research coordinator: Jessica Hamann
Contact: (310) 248-6737

The purpose of this study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.


Bladder Cancer

A PHASE III BLINDED STUDY OF IMMEDIATE POST-TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II SUPERFICIAL BLADDER CANCER

Principal investigator: Hyung L. Kim, M.D.
Research coordinator: Melanie Ozaki
Contact: (310) 248-7698

Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. This trial is studying gemcitabine to see how well it works when given directly into the bladder compared with a placebo after surgery in treating patients with newly diagnosed or recurrent bladder cancer.